Anzeige
Mehr »
Login
Sonntag, 24.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Microsofts, Googles und Amazons nukleares Wettrennen macht diese Uranaktie zu einem Muss!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P4CA | ISIN: CA6532261006 | Ticker-Symbol:
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
NEWTOPIA INC Chart 1 Jahr
5-Tage-Chart
NEWTOPIA INC 5-Tage-Chart
PR Newswire
88 Leser
Artikel bewerten:
(0)

Newtopia Inc.: Newtopia Reports Second Quarter 2024 Financial Results

Finanznachrichten News

Newtopia is well-positioned to grow and create value in key market opportunities at the forefront of global healthcare:

  • Growth of GLP-1s: Our engagement expertise provides unique ability to facilitate sustainable health outcomes and demonstrable ROI to GLP-1 sponsors
  • Rise of Health AI: Our unique data sets and capabilities will enrich and accelerate progress of next-gen clinical discovery platforms
  • Commercial and Community Care-Delivery: We see continued expansion with our market-leading employer, provider and provincial innovation partners

TORONTO, Aug. 8, 2024 /PRNewswire/ - Newtopia Inc. ("Newtopia" or the "Company") (TSXV: NEWU) (OTCQB: NEWUF), a tech-enabled whole health platform creating sustainable habits that prevent, slow and reverse chronic disease, today announced its second quarter 2024 financial results, operational highlights and filing of its financial statements. These results pertain to the three months ended June 30, 2024. All amounts are expressed in Canadian dollars, unless otherwise noted.

Second Quarter 2024 Financial Highlights (vs. Q2 2023):

  • Revenue of $1.6 million, as compared to $2.4 million
  • Gross Profit margin of 48%, as compared to 50%
  • Opex reduction of 18% year over year

"Over the last eleven years Newtopia's habit change solution has repeatedly proven our unique ability to produce industry leading patient engagement and to cultivate in our users the healthy habits that can prevent, slow and even reverse chronic metabolic disease. We've positioned ourselves at the forefront of healthcare developments, strengthened underlying operations, and evolved with value-based industry needs. As the economy strengthens Newtopia will be best positioned to support the innovative payers looking to drive proven health outcomes."

"Beginning with our industry-first randomized, controlled clinical trial between 2013-2016 and extending to the Fortune 500 employers that have adopted our solution, Newtopia has consistently delivered weight loss and reductions in A1C in participants that are not only clinically significant, but also sustainable over time. This has translated into meaningful cost-savings for our employer-partners and program sponsors and improved the health and well-being for the more than 100,000 individuals whom we have served, irrespective of their setting, geography, healthy equity or socio-economic status. Most recently, Newtopia reported six-month outcomes from its trial with Heartland Whole Health Institute in which we delivered our best-ever engagement rates and weight loss outcomes in both provider and employer environments."

"On the strength of this foundation, we are pursuing three distinct and significant opportunities to accelerate Newtopia's growth including: (1) expanding our key innovation partnerships with providers, employers and provincial payers; (2) combining Newtopia's proven habit change platform with GLP-1 drugs for obesity and type 2 diabetes; and (3) partnering with health AI and clinical discovery innovators to improve our collective ability to deliver best in breed outcomes that prevent, reverse and slow chronic disease", said Jeff Ruby, Founder and CEO of Newtopia.

Second Quarter 2024 Financial Results

Revenue for the three months ended June 30, 2024 was $1.6 million, compared to $2.4 million in the prior-year period. This decline was driven by a change made by a client with a long-standing incentive program, which the Company is actively working to offset.

Gross profit for the second quarter 2024 totaled $0.8 million, as compared to $1.2 million in the prior-year period. Gross profit is comprised of Newtopia's revenue less the cost of Welcome Kits sold to new participants, labor costs associated with the Company's coaching team of Inspirators, and amortization on the Company's capitalized technology investments.

Operating expenses for the three months ended June 30, 2024 totaled $1.5 million, compared to $1.8 million in the prior-year period. For the second quarter, the Company posted an operating loss of $727 thousand, compared to a loss of $436 thousand in the prior year period.

The Company ended the second quarter 2024 with $0.52 million in cash, with additional access to their revolving line of credit with a Canadian Schedule 1 bank.

2024 Outlook

Despite a challenging macro environment, the Company remains bullish regarding its strategic fit within the broader healthcare industry. Newtopia will continue to execute on its pipeline to return to EBITDA positive.

Conference Call

The Company will host a conference call on August 8th at 5 p.m. Eastern Time to discuss the second quarter 2024 results in further detail. To access the conference call, please dial (800) 717-1738 (U.S.) or (646) 307-1865 (International) 10 minutes prior to the start time and reference Conference ID number 04296. The call will also be available via live webcast on the investor relations portion of the Company's website located at investor.newtopia.com.

A replay of the conference call will be available through August 29, 2024, which can be accessed by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (International) and entering the passcode 11156555. The webcast will also be archived on the Company's website.

About Newtopia

Newtopia is a personalized whole health platform helping people create positive lifelong habits that prevent, slow, or reverse chronic disease while reducing healthcare costs. The platform leverages genetic, social and behavioral insights to create individualized prevention programs with a focus on metabolic disease, diabetes, mental health challenges, hypertension, weight management and musculoskeletal disorders. With a person-centered approach that combines virtual care, digital tools, connected devices and actionable data science, Newtopia delivers sustainable clinical and financial outcomes. Newtopia serves some of the largest nationwide employers and health plans and is currently listed in Canada on the TSX Venture Exchange (TSXV: NEWU) and is quoted in the US on the OTCQB® Venture Market (OTCQB: NEWUF). To learn more, visit newtopia.com, LinkedIn or X.

Forward Looking Statements

This news release contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, and forward looking statements, within the meaning of applicable United States securities legislation (collectively, "forward-looking statements"), which reflects management's expectations regarding Newtopia's future growth, results from operations (including, without limitation, future production and capital expenditures), performance (both operational and financial) and business prospects and opportunities. Wherever possible, words such as "predicts", "projects", "targets", "plans", "expects", "does not expect", "budget", "scheduled", "estimates", "forecasts", "anticipate" or "does not anticipate", "believe", "intend" and similar expressions or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. All statements other than statements of historical fact may be forward- looking information. Such statements reflect Newtopia's current views and intentions with respect to future events, based on information available to Newtopia, and are subject to certain risks, uncertainties, and assumptions. Material factors or assumptions were applied in providing forward-looking information. While forward-looking statements are based on data, assumptions and analyses that Newtopia believes are reasonable under the circumstances, whether actual results, performance or developments will meet Newtopia's expectations and predictions depends on a number of risks and uncertainties that could cause the actual results, performance and financial condition of Newtopia to differ materially from its expectations. Forward-looking statements are not a guarantee and are based on a number of estimates and assumptions management believes to be relevant and reasonable, whether actual results, performance or developments will meet Newtopia's expectations and predictions depends on a number of risks and uncertainties that could cause the actual results, performance and financial condition of Newtopia to differ materially from its expectations. Certain of the "risk factors" that could cause actual results to differ materially from Newtopia's forward-looking statements in this press release include, without limitation: the termination of contracts by clients, risks related to COVID-19 including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, quarantines, self-isolations, shelters- in-place and social distancing, disruptions to markets, economic activity, financing, supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession; and other general economic, market and business conditions and factors, including the risk factors discussed or referred to in Newtopia's disclosure documents, filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedarplus.ca including Newtopia's final long form prospectus dated March 30, 2020.

For more information on these risks please see the "Risk Factors" in Newtopia's final long-form prospectus dated March 30, 2020. Should any factor affect Newtopia in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Newtopia does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this news release is made as of the date of this news release, and Newtopia undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Key Financial Measures and Schedule of Non-GAAP Reconciliations
Unaudited Gross Profit Information- including
amortization



Three Months Ended June 30


Six Months Ended June 30



2024


2023


2024


2023



$


$


$


$

Revenue


1,568,970


2,357,034


3,382,970


5,005,691

Cost of revenue


(808,397)


(1,184,993)


(1,707,793)


(2,460,675)

Gross profit


760,573


1,172,041


1,675,177


2,545,016










Gross profit margin


48 %


50 %


50 %


51 %

Reconciliation of Total Operating Expenses to Adjusted Operating Expenses


Three Months Ended June 30,


Six Months Ended June 30,


2024


2023


2024


2023


$


$


$


$

Total expenses

1,936,354


2,403,354


4,060,329


5,149,156

Add (Subtract)








Share-based compensation

(67,425)


(215,013)


(141,090)


(308,303)

Depreciation of property and equipment

(735)


(2,030)


(1,470)


(3,579)

Interest and accretion expense

(275,963)


(177,728)


(543,324)


(347,423)

Interest on lease obligations

-


(8,973)


-


(21,563)

Finance charges

(110,664)


(122,318)


(239,689)


(231,966)

Amortization of deferred finance charges

(27,887)


(33,975)


(85,900)


(67,790)

Foreign exchange gain (loss)

34,057


(35,821)


30,749


(54,093)

(Loss) Gain on settlement of related party payable

-


7,203


(9,797)


7,203









Adjusted operating expenses

1,487,737


1,814,699


3,069,808


4,121,642

Unaudited Adjusted Operating Loss



Three Months Ended June 30


Six Months Ended June 30



2024


2023


2024


2023



$


$


$


$

Gross profit


760,573


1,172,041


1,675,177


2,545,016

Add back amortization of intangible asset


-


206,514


-


413,028

Adjusted gross profit


760,573


1,378,555


1,675,177


2,958,044

Adjusted operating expenses


(1,487,737)


(1,814,699)


(3,069,808)


(4,121,642)










Adjusted operating loss


(727,164)


(436,144)


(1,394,631)


(1,163,598)
















Newtopia Inc.
Condensed Interim Consolidated Statements of Financial Position (Unaudited)
As at June 30, 2024 and December 31, 2023
(Expressed in Canadian Dollars)



June 30,


December 31,



2024


2023



$


$

Assets




Current assets





Cash

519,927


387,339


Trade and other receivables

430,176


1,400,959


Contract assets

4,044


259,072


Prepaid expenses and deposits

254,018


101,043


Inventories

156,268


115,232


Deferred costs

25,233


64,583








1,389,666


2,328,228







Property and equipment

3,195


4,665








1,392,861


2,332,893






Liabilities




Current liabilities





Trade and other payables

2,223,873


1,825,356


Credit facility

4,745,798


4,767,006


Deferred revenue

-


48,185


Debentures

3,996,311


3,723,530



10,965,982


10,364,077







Debentures

1,438,364


1,387,476



12,404,346


11,751,553






Shareholders' Equity (Deficit)





Common shares

49,754,858


49,404,596


Contributed surplus

14,593,253


14,151,188


Deficit

(75,359,596)


(72,974,444)



(11,011,485)


(9,418,660)



1,392,861


2,332,893

Newtopia Inc.
Condensed Interim Consolidated Statements of Loss and Comprehensive Loss (Unaudited)
Six Months Ended June 30, 2024
(Expressed in Canadian Dollars)



2024

2023



$

$

Revenue

3,382,970

5,005,691

Cost revenue


1,707,793

2,460,675

Gross profit


1,675,177

2,545,016





Operating expenses



Technology and development

820,640

1,444,772

Sales and marketing

458,216

777,432

General and administrative

1,790,952

1,899,438

Share-based compensation

141,090

308,303

Depreciation of property and equipment


1,470

3,579



3,212,368

4,433,524

Other expenses (income)



Interest on lease obligations

-

21,563

Interest and accretion expense

543,324

347,423

Finance charges

239,689

231,966

Foreign exchange (gain) loss

(30,749)

54,093

(Gain) Loss on settlement of related party payable

9,797

(7,203)

Amortization of deferred finance charges

85,900

67,790







847,961

715,632





Net loss and comprehensive loss

(2,385,152)

(2,604,140)





Loss per share



Basic and diluted loss per share

(0.01)

(0.02)





Weighted average number of shares outstanding




Basic and diluted

168,425,358

141,046,080

Newtopia Inc.
Condensed Interim Statements of Cash Flows (Unaudited)
Six Months Ended June 30, 2024
(Expressed in Canadian Dollars)




Six Months Ended June 30




2024

2023






Cash flows used in operating activities




Net loss and comprehensive loss

(2,385,152)

(2,604,140)


Items not involving cash





Depreciation of property and equipment

1,470

3,579



Amortization of intangible asset

-

413,028



Amortization of deferred finance charge

85,900

67,790



Debenture interest and accretion expense

323,665

252,648



Interest on lease obligations

-

21,563



Share-based compensation

141,090

308,303



(Gain) Loss on settlement of related party payable

9,797

(7,203)




(1,823,230)

(1,544,432)


Change in non-cash working capital





Trade and other receivables

970,783

37,266



Prepaid expenses and deposits

(152,975)

(53,322)



Inventories

(41,036)

185,395



Trade and other payables

398,516

(10,602)



Deferred revenue

(48,185)

-



Contract asset/liability

255,028

270,100




(441,099)

(1,115,595)

Cash flows used in investing activities





Purchase of property and equipment

-

(1,099)




-

(1,099)

Cash flows from financing activities





Credit facility withdrawals

2,737,120

2,864,097



Credit facility repayments

(2,758,323)

(2,877,729)



Credit facility financing costs

(46,550)

(29,160)



Repayment of lease obligation

-

(357,186)



Proceeds from private placement offering, net of costs

641,440

1,467,295









573,687

1,067,317

Increase (decrease) in cash

132,588

(49,377)

Cash, beginning of period

387,339

345,950

Cash, end of period

519,927

296,573

SOURCE Newtopia Inc.

© 2024 PR Newswire
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.